The Uzbek Agency for the Development of the Pharmaceutical Industry and project developer Yangi Osiyo Biofarmatsevtika discussed progress on building a blood plasma medicine manufacturing plant in the Samarqand region. Discussions focused on schedule adherence and quality assurance, including technical support from specialists from the People's Republic of China.
Abdulla Azizov, Director of the Agency for the Development of the Pharmaceutical Industry of Uzbekistan, held talks with the management of Yangi Osiyo Biofarmatsevtika. The company is developing a production facility for blood plasma-based medicines in the Samarqand region. The discussion focused on the current construction status and ensuring the timely commissioning of the production complex.
Specific attention was given to organizing subsequent project stages, including the engagement of qualified specialists from the People's Republic of China. These experts are to assist with the installation and commissioning of technological equipment, as well as mounting, electrical, and plumbing works. The implementation of purification systems is also part of the agreed measures.
Both parties reaffirmed their intention to continue cooperation to implement the project efficiently and within the established deadlines. A central goal is ensuring a high quality level for the produced pharmaceutical products. The talks served to coordinate the necessary steps for the completion of the venture.
Project: Blood Supply and Plasma Production · Uzbekistan · Under construction
Key facts
- Project location: Samarqand Region, Uzbekistan
- Product: Blood plasma-based medicines
- Developer: Yangi Osiyo Biofarmatsevtika
- Support: Specialists from the People's Republic of China